Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
NEW HAVEN, Conn., December 04, 2008 /PRNewswire-FirstCall/ -- today made several announcements related to events in connection with the 50th American Society of Hematology Annual Meeting at the Moscone Center in San Francisco from December 6-9, 2008.
The Company announced that it would present survival data for its lead anticancer product laromustine in a poster presentation.
Title: "Survival After Complete Response to Treatment with
Laromustine (Cloretazine(R)) in Elderly Patients with Poor
Risk Acute
Myelogenous Leukemia"
Date: Saturday, December 6
Time: 9:30 a.m. to 7:30 p.m. (authors present 5:30-7:30 p.m.)
Location: Moscone Center Hall A, Board I-45
Vion will introduce Onrigin(TM) as the new trade name for laromustine at the Meeting, replacing Cloretazine(R) (VNP40101M).
The Company is co-sponsoring a seminar at the Meeting, in conjunction with MGI Pharmaceuticals and the Geriatric Oncology Consortium, entitled "Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem." The seminar will take place in Rooms 3009, 3011, 3022 and 3024 on Friday, December 5 from 12:30 p.m. to 4:30 p.m. at the Moscone Center West.
The Company announced that additional posters presented by investigators would be made on laromustine and Triapine(R), its second anticancer agent in clinical trials.
Title: "Preliminary Results from a Phase II Trial of Triapine(R)
Plus Fludarabine for Adults with Aggressive
Myeloproliferative Disorders"
Date: Sunday, December 7
Time: 9:00 a.m. to 8:00 p.m. (authors present 6:00-8:00 p.m.)
Location: Moscone Center Hall A, Board II-905
Title: "A Retrospective Comparison of Matched Elderly Patients
Treated with Laromustine (Cloretazine(R)) or Best
Supportive Care or Low-Dose Ara-C in the LRF AML14 Trial"
Date: Monday, December 8
Time: 10:30 a.m. to 7:30 p.m. (authors present 5:30-7:30 p.m.)
Location: Moscone Center Hall A, Board III-42
Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Onrigin(TM) (laromustine), formerly known as Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated poor-risk acute myelogenous leukemia. Clinical trials of Onrigin(TM) (laromustine) with cytarabine in elderly patients with acute myelogenous leukemia, with standard remission-induction therapy in patients with AML and myelodysplatic syndromes (MDS), with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.
COMPANY CONTACT: Vion Pharmaceuticals, Inc.
Alan Kessman, Chief Executive Officer
Howard B. Johnson, President & CFO
(203) 498-4210 phone
CONTACT: Alan Kessman, Chief Executive Officer, Howard B. Johnson,President & CFO, both of Vion Pharmaceuticals, Inc., +1-203-498-4210
Web site: http://www.vionpharm.com/
Ticker Symbol: (NASDAQ-OTCBB:VION),(NASDAQ-OTCBB:VION)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
